Medtronic 2014 Annual Report Download - page 13

Download and view the complete annual report

Please find page 13 of the 2014 Medtronic annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 147

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147

Beating Heart Surgery. To assist physicians performing beating heart surgery, we offer positioning and stabilization
technologies. These technologies include our Starfish 2 and Urchin heart positioners, which are designed to work in concert
with our family of Octopus tissue stabilizers.
Surgical Ablation. Our Cardioblate surgical ablation system, which includes the Cardioblate LP surgical ablation system,
Cardioblate navigator tissue dissector, and Cardioblate Cryoflex system, allows cardiac surgeons to create ablation lines during
cardiac surgery.
The charts below set forth net sales of our Structural Heart products as a percentage of our total net sales for each of the last
three fiscal years:
Fiscal Year 2012
(dollars in millions)
Structural Heart
$1,094
All Other
$15,090
Fiscal Year 2013
(dollars in millions)
All Other
$15,457
Structural Heart
$1,133
Fiscal Year 2014
(dollars in millions)
All Other
$15,793
Structural Heart
$1,212
7%
93%
7%
93%
7%
93%
Customers and Competitors
The primary medical specialists who use our Structural Heart products are cardiac surgeons and interventional cardiologists.
Our primary competitors in the Structural Heart business are Edwards Lifesciences Corporation (Edwards), St. Jude, Sorin,
Maquet Medical Systems, which is part of the publicly-listed Swedish group of companies GETINGE AB, and Terumo Medical
Corporation.
Endovascular
The Endovascular business is comprised of a comprehensive line of products and therapies to treat aortic disease (such as
aneurysms, dissections, and transections) as well as peripheral vascular disease (PVD). Our products include endovascular stent
graft systems, peripheral stent and angioplasty systems, and carotid embolic protection systems for the treatment of vascular
disease outside the heart.
The following are the principal products offered by our Endovascular business:
Endovascular Stent Grafts. An endovascular stent graft is a minimally invasive device to treat aortic disease such as an aortic
aneurysm, which is a weakened and bulging area in the aorta, the major blood vessel that feeds blood to the body. Our products
are designed to treat aortic aneurysms in either the abdomen (AAA) or thoracic (TAA) regions of the aorta. Our product line
includes a range of endovascular stent grafts and accessories including the market-leading Endurant II abdominal stent graft
system and the Valiant Captivia thoracic stent graft system.
Peripheral Vascular Intervention (PVI). PVI encompasses a variety of procedures to treat patients with PVD, a narrowing or
blockage of vessels outside the heart which impedes blood supply to the brain, kidneys, legs, and other vital organs. Similar to
CAD, PVD is commonly treated with balloon angioplasty which can be followed up with a peripheral stent. Our primary PVI
products include percutaneous angioplasty balloons including the IN.PACT family of drug-coated balloons, as well as stents
such as the Complete SE Vascular Stent and the Assurant Cobalt Iliac Stent.
5